Acadia Pharmaceuticals Inc (ACAD)

전일 마감가:

$17.08

열려 있는:

$17.44

하루 거래량:

1.15M

시가총액:

$2.82B

수익:

$726.44M

순이익/손실:

$-61.29M

주가수익비율:

-18.53

EPS:

-0.92

순현금흐름:

$-23.35M

1주 성능:

+2.03%

1개월 성능:

-7.44%

6개월 성능:

-29.16%

1년 성능:

-19.58%

1일 변동 폭

$17.03

$17.58

52주 변동 폭

$16.16

$33.99

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

명칭

Acadia Pharmaceuticals Inc

부문

Healthcare (1213)

산업

Biotechnology (699)

전화

858-558-2871

주소

3611 Valley Centre Drive, Suite 300, San Diego

직원

410

트위터

@acadiapharma

다음 수익 날짜

2024-05-08

최신 SEC 제출 서류

ACAD's Discussions on Twitter

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2024-01-30	개시	Robert W. Baird	Outperform
2024-01-24	업그레이드	Needham	Hold → Buy
2023-12-19	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2023-12-14	다운그레이드	Deutsche Bank	Buy → Hold
2023-12-13	개시	Citigroup	Buy
2023-12-12	개시	Deutsche Bank	Buy
2023-11-06	업그레이드	Mizuho	Neutral → Buy
2023-10-17	개시	UBS	Buy
2023-10-10	업그레이드	JP Morgan	Neutral → Overweight
2023-01-03	업그레이드	Guggenheim	Neutral → Buy
2022-11-04	다운그레이드	Goldman	Neutral → Sell
2022-11-01	개시	Loop Capital	Hold
2022-08-08	다운그레이드	Citigroup	Buy → Neutral
2022-08-05	다운그레이드	Citigroup	Buy → Neutral
2022-06-21	다운그레이드	Jefferies	Buy → Underperform
2022-06-16	업그레이드	Jefferies	Hold → Buy
2022-03-16	업그레이드	Canaccord Genuity	Hold → Buy
2022-02-09	업그레이드	H.C. Wainwright	Neutral → Buy
2022-01-05	업그레이드	Citigroup	Neutral → Buy
2021-12-21	다운그레이드	Guggenheim	Buy → Neutral
2021-11-01	업그레이드	Guggenheim	Neutral → Buy
2021-10-14	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2021-09-23	재개	Needham	Hold
2021-06-10	개시	Berenberg	Hold
2021-04-07	다운그레이드	H.C. Wainwright	Buy → Neutral
2021-04-06	다운그레이드	Canaccord Genuity	Buy → Hold
2021-04-06	다운그레이드	Goldman	Buy → Neutral
2021-04-06	다운그레이드	Jefferies	Buy → Hold
2021-04-06	다운그레이드	Mizuho	Buy → Neutral
2021-04-05	다운그레이드	Raymond James	Outperform → Mkt Perform
2021-03-10	다운그레이드	BofA Securities	Buy → Neutral
2021-03-09	다운그레이드	Citigroup	Buy → Neutral
2021-03-09	다운그레이드	Guggenheim	Buy → Neutral
2021-03-09	재확인	H.C. Wainwright	Buy
2021-03-09	다운그레이드	Raymond James	Strong Buy → Outperform
2021-03-09	다운그레이드	Stifel	Buy → Hold
2020-12-16	개시	Mizuho	Buy
2020-11-16	업그레이드	Raymond James	Outperform → Strong Buy
2020-08-25	개시	Raymond James	Outperform
2020-08-20	개시	Morgan Stanley	Overweight
2020-07-07	업그레이드	Stifel	Hold → Buy
2020-04-16	개시	Jefferies	Buy
2020-03-31	업그레이드	Goldman	Neutral → Buy
2020-03-06	개시	Citigroup	Buy
2019-12-16	개시	Guggenheim	Buy
2019-10-24	개시	Oppenheimer	Perform
2019-10-01	개시	RBC Capital Mkts	Outperform
2019-09-13	업그레이드	SVB Leerink	Mkt Perform → Outperform
2019-09-10	업그레이드	Canaccord Genuity	Hold → Buy
2019-07-23	재확인	Needham	Buy
2018-12-10	개시	Canaccord Genuity	Hold
2018-09-21	업그레이드	Piper Jaffray	Neutral → Overweight
2018-08-09	재확인	Stifel	Hold
2018-08-07	개시	Stifel	Hold
2018-08-06	다운그레이드	Piper Jaffray	Overweight → Neutral
2017-10-06	재개	Goldman	Neutral

모두보기

Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스

Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?

Zacks Investment Research

Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?

Zacks Investment Research

ACADIA Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (25 Ratings)

Benzinga

Cracking The Code: Understanding Analyst Reviews For ACADIA Pharmaceuticals

Benzinga

Why Is Acadia (ACAD) Down 23.4% Since Last Earnings Report?

Zacks Investment Research

Expert Ratings For ACADIA Pharmaceuticals

Benzinga

Acadia Pharmaceuticals Inc (ACAD) 재무 분석

Acadia Pharmaceuticals Inc (ACAD) 매출 2024

Acadia Pharmaceuticals Inc (ACAD) 순이익 2024

Acadia Pharmaceuticals Inc (ACAD) 현금흐름 2024

Acadia Pharmaceuticals Inc (ACAD) 주당 순이익 2024